Literature DB >> 23107103

Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas.

Ulrike Lass1, Christian Hartmann, David Capper, Christel Herold-Mende, Andreas von Deimling, Maren Meiboom, Wolf Mueller.   

Abstract

Recent studies imply the importance of rapid and reliable diagnostic assessment of 1p/19q status in oligodendroglial tumors. To date, fluorescence in situ hybridization (FISH) is the most commonly applied technique. FISH, however, has several technical shortcomings that are suboptimal for diagnostic applications: results must be viewed in a fluorescence microscope, results are usually evaluated by a single investigator only, and signal fading excludes physical archiving. Also, in gliomas, the distinction of diffusely infiltrating tumor cells from reactively altered normal tissue may be challenging in fluorescence microscopy. Dual-color chromogenic in situ hybridization (CISH) has started to replace FISH in some diagnostic tests performed in pathology. Here, we present the first single institute experience with a side-by-side analysis of 1p/19q FISH and CISH in a series of 42 consecutive gliomas. FISH and CISH produced identical results for 1p and 19q in 93% of cases (n = 39/42). Discrepant results were reevaluated by repeated FISH and a polymerase chain reaction (PCR)-based microsatellite marker analysis for loss of heterozygosity. Reevaluation confirmed CISH data in all three cases. We conclude that CISH is a reliable alternative in 1p/19q testing in paraffin-embedded tissues likely to be more sensitive to detect 1p/19q status than FISH analysis.
© 2012 The Authors; Brain Pathology © 2012 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107103     DOI: 10.1111/bpa.12003

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  13 in total

1.  Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.

Authors:  Ji Xiong; Wenli Tan; Jianbo Wen; Jiawei Pan; Yin Wang; Jun Zhang; Daoying Geng
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

Review 2.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

3.  Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors.

Authors:  Irena Srebotnik-Kirbiš; Clara Limbäck-Stokin
Journal:  J Neurooncol       Date:  2016-07-12       Impact factor: 4.130

4.  HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.

Authors:  Nazanin Sharifi; Arash Salmaninejad; Samira Ferdosi; Abolfazl Nesaei Bajestani; Malihe Khaleghiyan; Mehrdad Asghari Estiar; Mansour Jamali; Mohammad Reza Nowroozi; Abbas Shakoori
Journal:  Oncol Lett       Date:  2016-10-10       Impact factor: 2.967

5.  Disseminated oligodendroglial-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity [corrected].

Authors:  Matthias Preuss; Holger Christiansen; Andreas Merkenschlager; Franz Wolfgang Hirsch; Wieland Kiess; Wolf Müller; Stefanie Kästner; Andreas Henssler; Arnulf Pekrun; Holger Hauch; Michaela Nathrath; Jürgen Meixensberger; Torsten Pietsch; Klaus Kuchelmeister
Journal:  J Neurooncol       Date:  2015-02-12       Impact factor: 4.130

6.  T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings.

Authors:  Shinji Yamashita; Hideo Takeshima; Yoshihito Kadota; Minako Azuma; Tsuyoshi Fukushima; Natsuki Ogasawara; Tomoki Kawano; Mitsuru Tamura; Jyunichiro Muta; Kiyotaka Saito; Go Takeishi; Asako Mizuguchi; Takashi Watanabe; Hajime Ohta; Kiyotaka Yokogami
Journal:  Brain Tumor Pathol       Date:  2022-04-28       Impact factor: 3.298

Review 7.  Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Authors:  Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

8.  Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.

Authors:  Miguel Angel Tejada Neyra; Ulf Neuberger; Annekathrin Reinhardt; Gianluca Brugnara; David Bonekamp; Martin Sill; Antje Wick; David T W Jones; Alexander Radbruch; Andreas Unterberg; Jürgen Debus; Sabine Heiland; Heinz-Peter Schlemmer; Christel Herold-Mende; Stefan Pfister; Andreas von Deimling; Wolfgang Wick; David Capper; Martin Bendszus; Philipp Kickingereder
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

9.  Multiparametric and multiregional diffusion features help predict molecule information, grade and survival in lower-grade gliomas: a feasibility study.

Authors:  Hai Lin; Yanwen Xu; Lei Chen; Peng Na; Weiping Li
Journal:  Br J Radiol       Date:  2019-08-09       Impact factor: 3.039

Review 10.  Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.

Authors:  Sebastian Brandner; Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Neuropathol Appl Neurobiol       Date:  2022-03-03       Impact factor: 6.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.